Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

Ibrutinib (PCI-32765)化学構造

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 47100
JPY 30200
JPY 163000
JPY 412000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(483)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明 Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
ターゲット
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. [1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. [2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells M{XDc2Z2dmO2aX;uJIF{e2G7 NYfudI9rOi53IN88US=> NVK0VZd1PiCq MWfJcohq[mm2aX;uJI9nKEy7bjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUnXjNUBk\WyuczDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O|c9N2F-
human WSU-NHL cells NEWwd3pEgXSxdH;4bYPDqGG|c3H5 MnfJO|IhcA>? NVu4ZlJbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hX1OXLV7IUEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA6KM7:TR?= MkXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human SU-DHL6 cells M321cGN6fG:2b4jpZ:Kh[XO|YYm= M{nnclczKGh? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUEx4IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNUig{txONg>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human DOHH2 cells NHm3V|JEgXSxdH;4bYPDqGG|c3H5 NGexXnY4OiCq NIXST5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFV0iKMjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VS5? NXH3fZFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells MXrGeY5kfGmxbjDhd5NigQ>? NUe4bW13OSCq MYTJcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG|c3H5MEBKSzVyPUCuNkDPxE1w NXLPd3lLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
human Ramos cells MYfGeY5kfGmxbjDhd5NigQ>? NGnnTXQyKGh? M3r0PWlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6= MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human Pfeiffer cells MVjGeY5kfGmxbjDhd5NigQ>? M3[1OVczKGh? NFzLOo1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR\mWrZn\ldkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yJI5ONg>? NWrTTlRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells NUPXV2NjTnWwY4Tpc44h[XO|YYm= Ml:yNUBp M17BU2lvcGmkaYTpc44hd2ZiaIXtZY4h\nWubD3s[Y5ofGhiQmTLJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNidYPpcochTkGPLWPyZ5Rq\GVicHXweIll\SCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDUVk1HWkWWIFHzd4F697zOIFnDOVA:OC53IH7NMi=> M4rXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Sf9 insect cells MVrGeY5kfGmxbjDhd5NigQ>? NFjtNJM3OCCvaX7z NUHOXWd{UUN3MDC9JFAvODByMzFOwG0> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
sf9 cells Mk\OSpVv[3Srb36gZZN{[Xl? MkTpTWM2OCB;IECuNFAxOyEQvF2= NHmyfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
Sf9 insect cells NUjzSnBXTnWwY4Tpc44h[XO|YYm= M17oUlYxKG2rboO= MYLJR|UxKD1iMD6wNFA{PCEQvF2= M1S3R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells NYP2c3dETnWwY4Tpc44h[XO|YYm= MVi2NEBucW6| Ml:wTWM2OCB;IECuNFAxOzRizszN M2XEcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Sf9 insect cells MoriSpVv[3Srb36gZZN{[Xl? NI\pPIc3OCCvaX7z M3yxVGlEPTBiPTCwMlAxODN2IN88US=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN|c9N2F-
Sf9 cells MU\GeY5kfGmxbjDhd5NigQ>? M3jKO|YxKG2rboO= MmLFTWM2OCB;IECuNFAxPCEQvF2= Mn3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Sf9 cells M4XhVmZ2dmO2aX;uJIF{e2G7 MVu2NEBucW6| MV7JR|UxKD1iMD6wNFA2KM7:TR?= MomyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
Ramos cells NVXtNoJoTnWwY4Tpc44h[XO|YYm= MXqxJIg> NILBU3RKSzVyIE2gNE4xODB3IN88US=> MmDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Sf9 cells MlrWSpVv[3Srb36gZZN{[Xl? M{DKO|YxKG2rboO= MV7JR|UxKD1iMD6wNFEh|ryP NGnUUpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Pfeiffer cells M{jaXmN6fG:2b4jpZ4l1gSCjc4PhfS=> MmTzO|IhcA>? M2jkfmdKPTBiPTCwMlAxOiEQvF2= M3XPVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
B cells NUCxS4E4TnWwY4Tpc44h[XO|YYm= NVnLeVlQOSCq NUXzWHRUUUN3MDC9JFAvODB2NjFOwG0> M{fnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmwPVg5Lz5|MEK5NFk5QDxxYU6=
Sf9 insect cells NU\XbFlFTnWwY4Tpc44h[XO|YYm= NUP6S2E6OiC2bzC2NEBucW6| NYXwPHVIU2liPTCwMlAxPDhizszN MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells MWrGeY5kfGmxbjDhd5NigQ>? NVXkO5VsOSCq NWrW[XJ2UUN3MDC9JFAvODB5NTFOwG0> NF\xbnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells MlHwSpVv[3Srb36gZZN{[Xl? NH3HS2w3OCCvaX7z M4fpTGlEPTBiPTCwMlAxQCEQvF2= NH;peYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells MkfiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M135RVczKGh? Mn34TWM2OCB;IECuNFEh|ryP MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
CD19+ B cells MkjMSpVv[3Srb36gZZN{[Xl? M4\RVlEhcA>? NFTHS5VKSzVyIE2gNE4xOTJizszN MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUe5PFIoRjJ7NEW3PVgzRC:jPh?=
Sf9 insect cells Mmj4SpVv[3Srb36gZZN{[Xl? NFfHUZQ3OCCvaX7z NETGd3lKSzVyIE2gNE4xOTJizszN NIK5fmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells MlTPSpVv[3Srb36gZZN{[Xl? MkLJNUBp M2XEd2lEPTBiPTCwMlAyPCEQvF2= MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells MVPGeY5kfGmxbjDhd5NigQ>? NFmycocyKGh? NHXr[nRKSzVyIE2gNE4xOTR2IN88US=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells MoLxSpVv[3Srb36gZZN{[Xl? MoTIOlAhdWmwcx?= NWS5c4lEUUN3MDC9JFAvODF4MTFOwG0> NEHlc5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
HCC827 cells MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NUniemVqPzJiaB?= NXzYb3ZiUUN3MDC9JFAvODN7IN88US=> M3rZe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
PC9 cells M3\4UGZ2dmO2aX;uJIF{e2G7 NH3wdVc4OiCq NHiye5dIUTVyIE2gNE4xPSEQvF2= NHnKd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells Ml;vSpVv[3Srb36gZZN{[Xl? MoPvOlAhdWmwcx?= M4Pwd2lEPTBiPTCwMlEh|ryP MkPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
H3255 cells MX;GeY5kfGmxbjDhd5NigQ>? NEDaTJY4OiCq NUPEfHNHT0l3MDC9JFAvOTFizszN MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BaF3 cells MXPGeY5kfGmxbjDhd5NigQ>? NFf0OXc4OiCq M2XwfmdKPTBiPTCwMlEzKM7:TR?= NX7yOG4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
BAF3 cells MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MnuyO|IhcA>? NH\NfVhIUTVyIE2gNE4yOiEQvF2= MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9 insect cells Mkf6SpVv[3Srb36gZZN{[Xl? MVq2NEBucW6| M1HTfmlEPTBiPTCwMlEzOyEQvF2= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Sf9 insect cells NVG3SnJqTnWwY4Tpc44h[XO|YYm= NXjHflMxPjBibXnudy=> MkLBTWM2OCB;IECuNVQ3KM7:TR?= M{HwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells MV7GeY5kfGmxbjDhd5NigQ>? NUO2[I9iPzJiaB?= M1vndWdKPTBiPTCwMlE3KM7:TR?= MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells MWnGeY5kfGmxbjDhd5NigQ>? MlPqOlAhdWmwcx?= NUfVfmJWUUN3MDC9JFAvOiEQvF2= MmW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
MV411 cells NEezOXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTHTVUxKD1iMD6yOUDPxE1? M2DkbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
MV4-11 cells M3PIOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4LOelczKGh? MmfHS2k2OCB;IECuN|Mh|ryP MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells NVL4OYZlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWnYZpBjPzJiaB?= NUXIVVYyT0l3MDC9JFAvOzNizszN NUDydZZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
DOHH2 cells M1TH[GN6fG:2b4jpZ4l1gSCjc4PhfS=> NYq1THpXPzJiaB?= NFTveJhIUTVyIE2gNE41OSEQvF2= NUDUcWpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
HCC827 cells M{XRfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWq5OkBp MUnFR|UxKD1iMD60OUDPxE1? NXTCSWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL6 cells MUTDfZRwfG:6aXPpeJkh[XO|YYm= M1\yWlczKGh? NX:5TY1bT0l3MDC9JFAvPThizszN MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
M07e cells MknzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHLS2k2OCB;IECuOVkh|ryP MlK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
NCI-H1975 cells NXrKc24zSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NUHhOmFxQTZiaB?= NF7oU3BGSzVyIE2gNE43PCEQvF2= NGPrXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
SU-DHL-2 cells NUO1XI5oT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7YbHJ2T0l3MDC9JFAvPjRizszN MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
HEK293T cells NXf4WVdbTnWwY4Tpc44h[XO|YYm= NV\mXJlCOSCq MVzJR|UxKD1iMD65JO69VQ>? MnTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Ramos cells NWO2emx2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NUDnWYxnPzJiaB?= M1vUUGlEPTBiPTCwMlkzKM7:TR?= M2THdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
BA/F3 cells MlrLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NVztXXFiPzJiaB?= MofoTWM2OCB;IEGg{txO Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
WSU-NHL cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= MUO3NkBp NIj2cVBIUTVyIE2gNU4xQSEQvF2= MkHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
NCI-H1975 cells MVvGeY5kfGmxbjDhd5NigQ>? NFi2OJU4OiCq NV;n[|ZOT0l3MDC9JFEvOiEQvF2= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 cells MlfZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MVm3NkBp M121cWlEPTBiPTCxMlI4KM7:TR?= NECzdYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N|Q2QDF:L3G+
Raji cells NWqxdXpNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Mkf1OFghcA>? Ml3vTWM2OCB;IEGuOFkh|ryP MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
Pfeiffer cells NHn3T|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PabWdKPTBiPTCxMlYh|ryP M17JPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
A431 cells MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NXP2OZRGQTZiaB?= NVHYZZh5TUN3MDC9JFIvOzhizszN MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells NHrj[WlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NG\HU284OiCq MWrHTVUxKD1iMj61JO69VQ>? NVL6WmgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
U937 cells NIj5enpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TRO2dKPTBiPTCyMlkh|ryP M3TScVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
NB4 cells NYnETXNoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17Y[WdKPTBiPTCzJO69VQ>? NVzwVXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Ramos cells MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVezUlVGT0l3MDC9JFMvPCEQvF2= MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
SKM1 cells M4jkVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfHTVUxKD1iMz62JO69VQ>? MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells NWfYbIhjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nuPGdKPTBiPTC0MlQh|ryP NFTRSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells NH7vUHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M2LGR|czKGh? NHzsVGlKSzVyIE2gOU4yPCEQvF2= NX\XN3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Ramos cells MnvkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NVnNcVM6PDhiaB?= NEPONnRKSzVyIE2gOU4yPCEQvF2= NF;SOos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Ramos cells MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NVeyOmY5PDhiaB?= M12ydGlEPTBiPTC1Mlg5KM7:TR?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Ramos cells NWLpO2JUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MWK3NkBp NFHwR2pKSzVyIE2gOk43OiEQvF2= NVTX[GNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
K562 cells NIX6TJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MkDzOFghcA>? NWGxOJlpUUN3MDC9JFcvPSEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells MkfERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYTkendTPDhiaB?= M2C3SGlEPTBiPTC4JO69VQ>? NXfhUYZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
Ramos cells MoDORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4ew[VQ5KGh? NXfDWZpJUUN3MDC9JFgvOTFizszN NIHtT5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
Ramos cells M2r2WWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NGTHdWo1QCCq NGK1bpZKSzVyIE2gPE4zPiEQvF2= M2fDWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O|I6PTxxYU6=
OCI-AML3 cells Mn3sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnnT4ZIUTVyIE2gPU4zKM7:TR?= MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells M2i2NGN6fG:2b4jpZ4l1gSCjc4PhfS=> NGOyPYI4OiCq NIXXTlNIUTVyIE2gNVAh|ryP NG\6WJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N|A2PTN:L3G+
BAF3 cells M{iyemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWK3NkBp MnH5S2k2OCB;IEGwJO69VQ>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells M{nKOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\uOlczKGh? NHrER3NIUTVyIE2gNVAh|ryP MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NAMALWA cells M4jBTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4DyZ|czKGh? MUDJR|UxKD1iMUCuOFUh|ryP MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
Ramos cells NVXMNXg1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NEn3dJc1QCCq NVnYWlVpUUN3MDC9JFEzNjZizszN NHruRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? Mn3zOFghcA>? M{PwNmlEPTBiPTCxOE4zKM7:TR?= NXnHU5ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
Raji cells MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MUi0PEBp NFPqUHFKSzVyIE2gNVUvOiEQvF2= MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
MIAPaCa2 cells MX3DfZRwfG:6aXPpeJkh[XO|YYm= MmrlN{Bl[Xm| M4PtbmlEPTBiPTCxOk43KM7:TR?= NWTZPZo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
HeLa cells Mn7JR5l1d3SxeHnjbZR6KGG|c3H5 NWS0VpJ3OyCmYYnz MXPJR|UxKD1iMU[uPEDPxE1? NHSxUIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Raji cells MnvSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4T5ZlQ5KGh? MknMTWM2OCB;IEG5MlMh|ryP NGDjXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells M4TY[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M2\pVFQ5KGh? M4DLOmlEPTBiPTCxPU4{KM7:TR?= M3KzN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Raji cells MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NFPKbI04OiCq MVnJR|UxKD1iMUmuOUDPxE1? NYTUd5lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Raji cells NEnNZpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1H2TFQ5KGh? NVPHOYVNUUN3MDC9JFE6NjVizszN MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN|c9N2F-
NAMALWA cells M{\HT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NHP2Umk4OiCq M{S5OmlEPTBiPTCxPU43KM7:TR?= NFyzWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
A2780 cells MX\DfZRwfG:6aXPpeJkh[XO|YYm= MorON{Bl[Xm| MYjFR|UxKD1iMkCuNUDPxE1? MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Raji cells NETyWIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NUnHfYp4PzJiaB?= Ml20TWM2OCB;IEKwMlg5KM7:TR?= M4fGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
A549 cells MkLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXv0XotWPzJiaB?= Mk\2TWM2OCB;IEKxMlc6KM7:TR?= NX3x[od6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
SW480 cells NV:5ZXZVS3m2b4TvfIlkcXS7IHHzd4F6 M4jR[VMh\GG7cx?= NFX1OXNKSzVyIE2gNlUvPiEQvF2= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Ramos cells MVrDfZRwfG:6aXPpeJkh[XO|YYm= MkfSNlQhcA>? NX\teZdzUUN3MDC9JFI5NjdizszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O|U9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. [1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. [4]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

Kinase Assays :

In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験:

[2]

- 合併
  • 細胞株: Chronic lymphocytic leukemia (CLL) cells
  • 濃度: 0.01-100 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
  • 投薬量: ≤50 mg/kg
  • 投与方法: Administered via p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Water Insoluble
Ethanol '45 mg/mL warmed '45
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 440.5
化学式

C25H24N6O2

CAS No. 936563-96-1
Storage powder
in solvent
別名 N/A
Smiles C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665115 Withdrawn Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 2021 Phase 2
NCT05105841 Recruiting Drug: Venetoclax|Drug: Ibrutinib|Drug: Obinutuzumab Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) AbbVie November 8 2021 Phase 2
NCT04876092 Recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC July 28 2021 Phase 1
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 10 2021 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答:

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: Ibrutinib (PCI-32765)を買う | Ibrutinib (PCI-32765) ic50 | Ibrutinib (PCI-32765)供給者 | Ibrutinib (PCI-32765)を購入する | Ibrutinib (PCI-32765)費用 | Ibrutinib (PCI-32765)生産者 | オーダーIbrutinib (PCI-32765) | Ibrutinib (PCI-32765)化学構造 | Ibrutinib (PCI-32765)分子量 | Ibrutinib (PCI-32765)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID